Verona Pharma: A Few Points From The Bull And Bear Case [Seeking Alpha]
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Seeking Alpha
VRNA had $257M in cash at the end of Q3'23, and a debt facility worth up to $400M was set up in early 2024. While VRNA has the funding to go it alone in the launch of the ensifentrine, a buyout is still a possibility. Verona Pharma plc ( NASDAQ: VRNA ) has submitted a marketing application to the US FDA for its drug ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This article takes a look at some of the bull and bear case points for VRNA. The Phase 3 studies Ensifentrine, an inhibitor of phosphodiesterase 3&4, produces both an anti-inflammatory effect and bronchodilation. Ensifentrine demonstrated its potential in COPD across several studies, notably the phase 3 ENHANCE studies. In ENHANCE-1 (n = 763 patients), treatment with ensifentrine significantly improved lung function relative to placebo, as measured by forced expiratory volume in one second (FEV1). With regards to moderate to severe COPD exacerbations over 24 weeks, ensifen
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 [Yahoo! Finance]Yahoo! Finance
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024GlobeNewswire
- Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswire
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market ResearchPR Newswire
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market ResearchPR Newswire
VRNA
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- VRNA's page on the SEC website